Pfizer (PFE) reported Q4 FY2022 earnings of $1.14 per share (versus $1.08 per share in Q4 FY2021), beating analysts’ consensus estimate of $1.04 per share.
The company’s quarterly revenues amounted to $24.300 bln (+1.9% y/y), roughly in line with analysts’ consensus estimate of $24.403 bln.
The company also issued downside guidance for FY 2023, seeing EPS of $3.25-$3.45 versus analysts’ consensus estimate of $4.38 and revenues of $67.0-$71.0 bln versus analysts’ consensus estimate of $74.23 bln.
PFE fell to $42.31 (-2.85%) in pre-market trading.
